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Summary The matrix metalloprotease MMP-9 localizes to tumour-associated macrophages in human ovarian cancer but little is known of its
regulation. Co-culture of human ovarian cancer cells (PEO-1) and a monocytic cell line (THP-1) led to production of 92-kDa proMMP-9. PEO-
1-conditioned medium (CM) also stimulated THP-1 cells or isolated peripheral blood monocytes to produce proMMP-9. Expression of TIMP-
1, however, remained unaffected. There was evidence that tumour necrosis factor alpha (TNF-a) was involved in tumour-stimulated
monocytic proMMP-9 production. Antibody to TNF-ax inhibited proMMP-9 production, and synthesis of TNF-a mRNA and protein preceded
proMMP-9 release. In addition, the synthetic matrix metalloprotease inhibitor (MMPI) BB-2116, which blocks TNF-a shedding, inhibited
proMMP-9 release in the co-cultures and from CM-stimulated monocytic cells. Further experiments suggested that the stimulating factor
present in CM was not TNF-ax, but acted synergistically with autocrine monocyte-derived TNF-ax to release monocytic proMMP-9. Thus,
ovarian cancer cells can stimulate monocytic cells in vitro to make proMMP-9 without affecting the expression of its inhibitor TIMP-1. This
induction is mediated via a soluble factor (provisionally named MMPSF) that requires synergistic action of autocrine or paracrine TNF-a.
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Matrix metalloproteases (MMPs) are a family of structurally and
functionally related endopeptidases. They have in common a zinc
ion at the active site and are released as an inactive pro-form
(zymogen). Proteolytic activation enables MMPs to degrade
components of the extracellular matrix, such as collagens,
fibronectin and laminin (for review Matrisian, 1990, 1992;
Woessner, 1991; Mauch et al, 1994; Murphy, 1995). Ofthe MMPs
cloned so far, the gelatinases MMP-2 and MMP-9 degrade in vitro
native type IV collagen, the main constituent of the basement
membrane. MMP activity is controlled at several levels. Gene
expression is regulated by cytokines, such as tumour necrosis
factor alpha (TNF-oc), transforming growth factor beta (TGF-,B)
and interferons (for review Matrisian, 1990, 1992; Woessner,
1991; Mauviel, 1993; Mauch et al, 1994; Murphy, 1995), activa-
tion of MMPs can be triggered in vitro by proteases and other
MMPs (Matrisian, 1990, 1992; Woessner, 1991; Mauch et al,
1994; Murphy, 1995; Sang et al, 1995) and, finally, their proteo-
lytic activity is counterbalanced by tissue inhibitors ofmetallopro-
teases (TIMPs) (Matrisian, 1990, 1992; Woessner, 1991; Mauch et
al, 1994; Murphy, 1995).
MMPs play an important role in tissue remodelling during
embryogenesis and wound healing (Matrisian, 1990, 1992; Bullen
et al, 1995). In addition, these enzymes contribute to the pathology
of chronic diseases, such as osteo- and rheumatoid arthritis
(Woessner, 1991; Woessner and Gunja Smith, 1991; Stetler
Stevenson, 1996), and malignancy (Liotta and Stetler Stevenson,
1991; Woessner, 1991; Stetler Stevenson, 1996). Events such as
angiogenesis, intra- and extravasation and migration of tumour or
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host immune cells have been associated with MMP activity (Liotta
and Stetler Stevenson, 1991; Karelina et al, 1995).
MMP-2 and -9 are present in biopsies of breast, bladder,
ovarian, colorectal and prostate cancer and their levels seem to be
related to tumour grade and invasion (Davies et al, 1993a and b;
Hamdy et al, 1994; Naylor et al, 1994; Liabakk et al, 1996).
However, relatively little is known about the mechanisms leading
to MMP expression in vivo. A recently published report describes
the interaction ofT cells and monocytes leading to MMP-9 release
(Kiener et al, 1995). A soluble factor, gp39, derived from T cells
was found to be responsible for triggering MMP-9 production via
monocytic CD40, the gp39-receptor.
The aim ofour study was to investigate the interactions between
human tumour cells and macrophages that lead to MMP-9 release.
In previous work on biopsies ofhuman ovarian cancer, the type IV
gelatinases MMP-2 and MMP-9 were detected by zymography
and their expression localized by in situ hybridization (Naylor et
al, 1994). MMP-2 mRNA was found exclusively in the tumour
stroma, whereas MMP-9 expression was discrete and seen in both
tumour and stromal areas. Immunohistochemical studies using an
antibody to the macrophage marker CD68 showed a positive
correlation with the pattern found for MMP-9, which suggested
that tumour-associated macrophages (TAMs) may be the source of
MMP-9 (Naylor et al, 1994). TNF-ax expression, as assessed by in
situ hybridization, was confined to epithelial tumour areas,
whereas immunoreactive TNF-ox protein was found in both tumour
and stromal areas. In this respect, the pattern of TNF-oc protein
was similar to that found for infiltrating macrophages (Naylor et
al, 1993). These results suggested that TAMs could be the source
of MMP-9 and that TNF-ox might play a role in its production
(Naylor et al, 1993, 1994).
In this report, we describe a mechanism that leads to monocytic
proMMP-9 but not to TIMP-1 production in the presence of
ovarian cancer cells. We provide evidence that a tumour-derived
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soluble factor, tentatively named MMPSF (matrix metallopro-
teinase-stimulating factor) demonstrates synergy with autocrine or
paracrine TNF-oc to stimulate MMP-9 release.
MATERIAL AND METHODS
Cell culture techniques
The human cell line PEO-1 was derived from ascites of a patient
with a poorly differentiated adenocarcinoma before chemotherapy
(Langdon et al, 1988). The cell line was maintained in RPMI
(Gibco, Paisley, UK) supplemented with 10% fetal calf serum
(FCS, Gibco) and 10 sg ml-' bovine insulin (Sigma, Poole, UK)
and routinely passaged two to three times per week. The human
monocytic cell line THP-1 was from ATCC (American Type
Culture Collection, Rockville, IL, USA) and maintained at a cell
concentration between 0.5 and lx106cells ml-' in RPMI
containing 10% FCS and 50 ltM beta-mercaptoethanol (Sigma).
All cells were grown in Nunc tissue culture flasks and incubated in
a humidified atmosphere at 37°C, 5% carbon dioxide.
Experimental cell culture conditions and preparation of
conditioned medium
PEO-1 cells were grown to near confluency, detached from the
tissue culture flask with trypsin/versene (Gibco), resuspended in
culture medium, pelleted (210 g, 5 min), washed up to three times
in phosphate-buffered saline (PBS) and resuspended in FCS-free
Aim V medium (Gibco). Similarly, THP-1 cells were pelleted
(210g, 5 min) and resuspended in FCS-free Aim V. Cells were
counted using a haemocytometer and, if not otherwise stated, the
cell concentration adjusted to 1x106 cells ml-'. All experiments
were set up in 24- or 96-well plates (Costar, Cambridge, MA,
USA) and cell culture supematant harvested, unless stated other-
wise, after an incubation period of 48 h. Supernatant was cleared
of cells and cell debris by centrifugation at 14 000 r.p.m. in a
microfuge before storage at -20°C or immediate use for zymog-
raphy. For use as conditioned medium (CM), the supernatant was
sterile filtered (Acrodisc 0.2 ,um, Gelman Sciences, Ann Arbor,
MI, USA) before freeze-storage or use.
Isolation of peripheral blood monocytes
Peripheral blood (50 ml) was taken from healthy volunteers by
venupuncture, mixed with 5 ml of 3.8% sodium citrate and
centrifuged (20 min, 300g) to obtain a cell pellet and platelet-rich
plasma (PRP). PRP was centrifuged twice (2000g, 10 min) to
remove the platelets (PPP, platelet-poor plasma) and stored on ice
for later use. The cellular pellet was resuspended in 0.9% sodium
chloride to 45 ml and erythrocytes precipitated with 5 ml of 6%
Dextran T-500 (Pharmacia, Uppsala, Sweden). The lymphocyte-
rich supernatant was transferred into a fresh tube, the cells pelleted
by centrifugation (5 min, 200g), washed three times in wash
buffer (0.9% sodium chloride, 10% PPP) and resuspended in 8 ml
of PPP. Two millilitres of cell suspension were under layered with
2 ml of 42% Percoll (Pharmacia) prepared with PPP. After
centrifugation (O min, 300g) the monocyte-rich interphase was
harvested by aspiration, washed three times in wash buffer and
resuspended in Aim V medium. The cells were seeded and after an
incubation period of 1 h at 37°C washed three times with Aim V
medium to select the monocytes by adhesion. To assess the purity
of the preparation, an aliquot of cells was set to adhere on a Petri
dish, washed in the same way as the cells used for the stimulation
experiments, air dried, stained using the oc-naphthyl acetate
esterase method (Yam et al, 1971) and counterstained with Meyers
haematoxylin. The ratio of monocytes vs non-monocytes was
determined by phase-contrast microscopy. In all experiments,
purity of monocytes exceeded 90%.
Endotoxin assessment
All solutions and buffers (RPMI, PBS, AIM V, water, CM, etc.) used
in cell culture were checked for endotoxin content using a kinetic
turbidity assay (BioWhittaker, Reading, UK) or the endotoxin detec-
tion kit (0.50 EU ml-') purchased from Associates of Cape Cod
(Woods Hole, MA, USA). Levels were found to be below
100 pg ml-'. Dose-response experiments of THP-1 cells to three
types of endotoxin (E. coli 055:B5, 01 1 :B4 and Scalmonella
minnesota) showed that levels of 100 pg ml-' orless did not stimulate
MMP-9 release in a detectable manner (data not shown). To achieve
levels of MMP-9 similar to those obtained in co-culture or CM
experiments with THP-I (> fivefold background level), I ng ml-' or
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Figure 1 ProMMP-9 production was increased in co-cultures of the
monocytic THP-1 cell line and the ovarian cancer cell line PEO-1 (1:1 ratio).
THP-1 and PEO-1 cells were seeded separately or in co-culture at a 1:1
ratio. The cell culture supernatant was harvested after 48 h and the proMMP-
9 production assessed by quantitative zymography. The left panel shows a
typical zymogram of cell culture supernatants, the right panel a Western blot
for MMP-9. B shows the quantitation of zymograms with respect to proMMP-
9. In co-culture, proMMP-9 stimulation exceeded background levels five- to
eightfold. Only proMMP-9 (92 kDa) can be detected. Left panel: lane 1,
purified MMP-9; lane 2, THP-1 supernatant; lane 3, PEO-1 supernatant; lane
4, THP-1/PEO-1 co-culture supernatant. Right panel: lane 1, purified MMP-9;
lane 2, THP-1 stimulated with CM derived from PEO-1 cells; lane 3, THP-
1/PEO-1 co-culture supernatant. Statistical analysis of B using Students t-
test: THP-1 vs THP-1/PEO-1, P= 0.039; PEO-1 vs THP-1/PEO-1, P= 0.034
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more of endotoxin was needed. Endotoxin levels present in FCS
were assessed by Gibco and were found to be below 100 pg ml-'.
Zymogram analysis
Quantitative gelatinolytic zymography was performed according
to an improved protocol described recently (Leber and Balkwill,
1997). For gel to gel comparison, a standard of commercially
available purified human proMMP-9 (TCS Biologicals, Botolph
Claydon, UK) was loaded on each gel in duplicate. All samples
were assessed in the linear range of the assay and the individual
MMP-9 activity expressed in ng (MMP-9) per ,ul (supernatant).
All values of MMP-9 activity were based on at least two indepen-
dent experiments. The error bars reflect the standard deviation.
Spin column experiment
SpinColumns-30 (Clontech, Basingstoke, UK) were pre-spun
twice for 3 min (4C, 1100g) to remove the equilibration buffer. A
50-lt aliquot of sample was loaded on the spin column and spun
for 5 min (4C, I 100g). The flow-through was harvested and the
volume adjusted to 55 ,tl with sterile PBS.
Immunoprecipitation of TNF-a
The monoclonal anti-TNF-oc antibody 6H 11 (kindly provided by
Dr N-B Liabakk, Trondheim, Norway) was added to CM or
control samples at a concentration of 5 ,ug ml-'. Samples were
incubated for at least 1 h at 4°C on a rotor, then 40gl ofprotein-G
Sepharose (Sigma) added and samples incubated as before. To
pellet the beads, samples were spun for 5 min at maximal speed in
a microfuge and the supernatant carefully removed. To assess the
MMP-9-inducing activity, the sample was added to THP-1 cells in
a 1:10 dilution. To check for the efficiency and specificity ofTNF-
ux precipitation, samples spiked with recombinant human TNF-ix
at a concentration of 10 ng ml-' were prepared. Precipitation of
TNF-oc and removal ofthe anti-TNF-ux antibody was complete and
specific. The experiments have been repeated with a commercially
available monoclonal anti-TNF-ox antibody (R&D Systems
Europe, Abingdon, UK) and an unrelated antibody of the same
antibody isotype.
RNA preparation and Northern blotting
Total RNA was isolated using TriReagent (Molecular Research
Center, Cincinnati, OH, USA) according to the manufacturers
instructions, 10 Htg heated to 65°C for 5 min, resolved on a 1%
denaturing formaldehyde-agarose gel and blotted onto a Hybond
N+ membrane (Amersham, Slough, UK) by capillary transfer as
described elsewhere (Balkwill, 1991). RNA was UV cross-linked
to the nylon membrane using a Stratalinker (Stratagene,
Cambridge, UK) and blots prehybridized and hybridized as
described (Balkwill, 1991). cDNA probes for human TNF-ox,
MMP-9 and 3-actin were radioactively labelled (32P-dCTP,
Amersham) by random priming using the Prime-It or the RmT-
Prime-It labelling kit (Stratagene) according to the manufacturers
instructions. After hybridization, blots were washed twice for
10 min at room temperature in 2 x standard saline citrate (SSC),
0.1I% sodium dodecyl sulphate (SDS), then incubated twice for 15
min in 0.1% SSC, 0.1% SDS at 65°C and finally washed for 10 min
in 2 x SSC at room temperature. For detection, blots were wrapped
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Figure 2 ProMMP-9 activity in co-culture supernatants depended on the
ratio of PEO-1 to THP-1 cells. Cells were diluted in doubling dilutions starting
from 1 x 106 cells ml-1 and added to 1 x 106 cells ml-' of the other cell line.
After 48 h, the cell culture supernatant was assessed by quantitative
zymography. Maximal proMMP-9 release was obtained at a 1:1 of ratio
tumour cells and monocytes. (The graph shows a typical experiment out of
four experiments performed.)
in Saranwrap (Dow Chemicals) and exposed at -70°C to BioMax
X-ray film (Kodak) for 4 to 56 h.
Detection of TNF-a protein
TNF-ox protein was detected using a WEHI-164 based bioassay
(Espevik and Nissen Meyer, 1986) or a commercially available
ELISA (R&D Systems Europe). A standard curve using recombi-
nant human TNF-oc was set up, and validation ofthe assay showed
that accurate results could be obtained in the range between 20 and
500 pg ml-' TNF-c for the bioassay and 15-1000 pg ml-' for the
ELISA.
Western blotting
Supernatants of THP-l/PEO-1 co-cultures and purified human
proMMP-9 were resolved on a 10% SDS-PAGE under reducing or
non-reducing conditions and electroblotted onto a nitrocellulose
membrane (Amersham) for 2 h at 45 V. After blocking of the
membrane with PBS containing 10% non-fat dry milk, the blots
were incubated with a monoclonal anti-human MMP-9 antibody
diluted 1:1000 (Ab-3, Oncogene Science) or 1:5000 (CA-209,
kindly provided by Dr Raphael Fridman, Wayne State University,
DT, USA) in PBS, 0.01% Tween-20. Immunodetection was
performed using the enhanced luminescence kit ECL (Amersham)
or with SuperSignal Ultra (Pierce, Chester, UK) according to the
manufacturers instructions.
Other materials
Recombinant TNF-ox, kindly provided by Knoll, Friedrichshafen,
Germany, was prepared as a 15 ,tg mll stock in PBS, 0.3% bovine
serum albumin (Sigma) and stored at -20°C. The synthetic MMP
inhibitor BB-2116 (a gift from British Biotech Pharmaceuticals,
Oxford, UK) was prepared in dimethyl sulphoxide (DMSO) as a
100 mm stock solution and diluted in PBS to, if not stated differ-
ently, a concentration of 30gM.
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Figure 3 PEO-1-derived conditioned medium (CM) induced proMMP-9
production by THP-1 cells in a dose-dependent manner. PEO-1-derived CM
was added to THP-1 cells in the dilutions indicated. After 48 h, the cell culture
supernatant was assessd by quantitative zymography. CM stimulated MMP-9
release from THP-1 cells in a dose-dependent manner. For all further
stimulation experiments, a 1:10 dilution of CM was used
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Figure 4 CM induced increased MMP-9 production in isolated peripheral
blood monocytes. Peripheral blood monocytes (PBM) were isolated as
described in Material and methods, stimulated with 10 x concentrated CM
and the cell culture supernatant analysed after an incubation period of 48 h.
The zymogram (left panel) shows two close together migrating activities that
were both enhanced in supernatant of CM-stimulated monocytes. Both
proteins were identified as MMP-9 by Western blotting using the monoclonal
anti-MMP-9 antibody CA-209 (right panel). In other experiments, only a
single band of proMMP-9 was detectable. Left panel: lane 1, proMMP-9; lane
2, unstimulated PBMs; lane 3, CM stimulated PBMs. Right panel: lane 1,
proMMP-9; lane 2, CM-stimulated PBMs)
RESULTS
Co-culture of ovarian cancer cells and monocytic cells
induces proMMP-9 independent from cell-cell contact
The co-culture system consisted of the ovarian cancer cell line
PEO- 1 and the monocytic cell line THP-1. As shown in Figure IA
and B, supernatants generated when these cells were cultured
alone contained low levels of the 92-kDa form of MMP-9 as
measured by quantitative zymography. However, co-culture at a
1:1 ratio of tumour cells to monocytes led to strong production
of proMMP-9 in supernatants. The identity of MMP-9 was
confirmed by Western blotting (Figure lA, right panel).
Experiments showed that this 1:1 ratio was optimal (Figure 2). For
a fixed number of PEO-1 cells, proMMP-9 release increased with
an increasing number ofTHP- 1 cells. For a fixed number ofTHP-
1 cells, proMMP-9 release slightly increased with an increasing
number of PEO-1 cells. Use of cell culture inserts (Millicell-CM,
Milipore), separating the two cell lines but allowing exchange of
soluble factors, led to similar strong induction of proMMP-9 as
co-cultures without the cell culture inserts (data not shown).
THP-1+CM
THP-1+CM5 + pg ml-1 TNF-AB
0 0.1 0.2 0.3
proMMP-9 (ng VI-1)
0.4
Figure 5 Inhibition of MMP-9 release by an anti-TNF-a antibody. THP-
1/PEO-1 co-cultures (A) and CM-stimulated THP-1 cells (B) were treated
with the monoclonal anti-TNF-a antibody 6H11 and the cell culture
(kDa) supernatant assessed by quantitative zymography. The antibody inhibits
proMMP-9 release in both THP-1/PEO-1 co-cultures and from CM-stimulated
97 THP-1 cells. Statistical analysis using paired Student's t-test: (A) THP-
1/PEO-1 vs THP-1/PEO-1 in presence of 5 gg ml-1 TNF-a antibody,
P= 0.028; THP-1/PEO-1 vs THP-1/PEO-1 in presence of 10 ,g ml-' TNF-a
68 antibody, P= 0.044. (B) THP-1 vs THP-1+CM, P< 0.001; THP-1 vs THP- 1+CM+ TNF-AB, P = 0.003)
MMP-9 is produced by the monocytic cells in the
co-cultures
These results suggested that cell-cell contact was not required and
that the monocytic cells were the source ofproMMP-9. To test this
further, we prepared conditioned medium (CM) from both PEO- 1
and THP-1 cells. CM from THP- I cells did not enhance MMP-9
release from PEO-1 (data not shown), whereas PEO-1-derived
CM induced proMMP-9 production by THP-1 (Figure 3). This
induction was dose dependent and CM even at a 1:60 dilution CM
had a clear proMMP-9-inducing effect on THP- 1 cells. The iden-
tity of the protein induced by CM was confirmed as MMP-9 by
Western blotting (Figure IA, right panel). Cell counting experi-
ments showed that the cell numbers in CM-stimulated and control
cultures were not significantly different (data not shown).
Peripheral blood monocytes (PBM) also produce
proMMP-9 in response to CM
Similar to the monocytic cell line THP-1, isolated peripheral blood
monocytes released increased amounts of proMMP-9 in response
to CM. However, to achieve the level of induction shown (Figure
4), CM had to be concentrated 10-fold by ultrafiltration (NanoSpin
Plus 10000 MWCO, Gelman Sciences, Ann Arbor, MI, USA).
TNF-a is involved in tumour-stimulated monocytic
MMP-9 production
Several lines of evidence suggested an involvement of the cytokine
TNF-ac in monocytic production ofMMP-9. First, recombinant TNF-
ox inducedproMMP-9production by THP-I cells in adose-dependent
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Figure 6 BB-2116 inhibits TNF-a release from LPS-stimulated THP-1 cells
and proMMP-9 release from CM-stimulated THP-1 cells or in co-cultures of
THP-1 and PEO-1. BB-2116 was added to LPS (100 ng ml-')-stimulated THP-
1 cells (A), THP-1/PEO1 co-cultures (B) and CM-stimulated THP-1 cells (C).
The cell culture supernatant was assayed for TNF-a (A) and MMP-9 (B and
C) after an incubation period of 48 h. The matrix metalloproteinase inhibitor
BB-2116 inhibits TNF-a release from LPS-stimulated THP-1 cells in a dose-
dependent manner (A: *, LPS + BB-2116; A, LPS; *, unstimulated). The
IC5 was 300 nm as determined by computer-assisted curve fitting. Further,
BB-2116 inhibits proMMP-9 release in a dose-dependent manner in both
co-cultures (B: IC5 590 nM, *, BB-2116; *, control) and CM-stimulated
THP-1 cells (C, IC50 860 nM, *, CM + BB-2116; 0, CM; A, unstimulated)
manner. ProMMP-9 release was first detected at 0.3 ng ml-' TNF-a
andreachedits maximum at 10 ng ml-' TNF-a(datanotshown). This
finding is consistent with published results (Okada et al, 1990;
Mauviel, 1993). TNF-a (10 ng ml-') had, however, a minimal effect
on MMP-9 release from PEO-1 cells (data not shown). Second, a
monoclonal antibody that neutralized TNF-oc bioactivity inhibited
MMP-9 release in co-cultures and also in CM-stimulated THP-1
cultures (Figure 5A and B).
In accordance with published results (Gearing et al, 1994, 1995),
we found that the matrix metalloprotease inhibitor BB-2116
blocked shedding ofTNF-ax from its membrane-spanning precursor
after LPS stimulation ofTHP-I cells (Figure 6A, IC50 300 nM). This
MMPI inhibited proMMP-9 production with a similar lC50 in co-
culture and in CM experiments (Figure 6B and C, IC 0 590 nm and
860 nM). At the concentrations used in these experiments, BB-2116
had no cytotoxic or cytostatic effects on THP-1 cells as assessed by
cell counting experiments (data not shown) and phase-contrast
microscopy. Further, BB-2116 did not interfere with zymogram
analysis of proMMP-9 in the assessed range (< 300 mm, data not
shown). The observation that an inhibitor of TNF-cx release also
inhibited proMMP-9 release from monocytic cells when stimulated
with CM led us to investigate a role for autocrine monocytic
TNF-oc production in proMMP-9 release.
Analysis of MMP-9, TIMP-1 and TNF-a gene expression
and protein
MMP-9 and TNF-ac gene expression and protein production was
studied in CM-stimulated and-unstimulated THP-I cells over48 hof
incubation. UsingNorthern analysis, MMP-9 mRNA was detected in
both CM-stimulated and -unstimulated THP-1 cells at 6 h. In unstim-
ulated cells, the signal remained weak and decreased to below the
detection limit after 24 h of incubation (Figure 7A). In CM-
stimulated cells, however, MMP-9 expression was strongly induced,
peaked at 14 h and remained strong until 48 h (Figure 7A). This
finding is consistent withprotein dataobtained by zymography. First,
proMMP-9 proteolytic activity was detected in the supernatant after
12 h, and levels seemed to increase steadily thereafter (Figure 7B).
Reprobing the above blot for TNF-a mRNA showed gene
expression in both CM-stimulated and -unstimulated THP-1 cells
with the same time course and level of expression (Figure 7A).
TNF-ax mRNA was not detectable at the beginning of culture,
peaked at 2 h and declined thereafter. TNF-a protein, as detected
by bioassay or ELISA in three independent experiments, followed
the pattern observed for mRNA. Maximal TNF-x protein was
detected 5-8 h after stimulation (60 pg ml' and 21 pg ml-' as
determined by bioassay and ELISA respectively). No TNF-a was
detected at the beginning ofthe incubation period and the amounts
decreased to the detection limit (ELISA, 15 pg ml-') or below
(bioassay, 19 pg ml-'; data not shown) by 16 h.
Reprobing of the same blot for TIMP-1 mRNA showed no
difference in TIMP-1 expression between unstimulated and CM-
stimulated THP-1 cells (Figure 7A). Reprobing of the blot with
P-actin showed that loading was even (Figure 7A).
Thus, these experiments showed that THP-1 cells release low
amounts ofTNF-a even without stimulation with CM.
The proMMP-9-stimulating activity (MMPSF) present in
CM is distinct from TNF-a
The level of TNF-a in different batches of CM was measured by
bioassay. This varied from 0 to 160 pg ml' without detectable
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Figure 7 Kinetics of proMMP-9, TNF-a and TIMP-1 gene
expression and protein production in unstimulated and CM-
stimulated THP-1 cells. THP-1 cells were stimulated 1:10 with
PEO-1-derived conditioned medium (CM) or remained
unstimulated. MMP-9, TIMP-1, ,-actin and TNF-a gene
expression was analysed by Northern blotting (A). MMP-9
expression was strong and sustained in CM-stimulated THP-1
cells only. TNF-a and TIMP-1 gene expression showed a
similar pattern in both CM-stimulated and -unstimulated THP-1
cells. Probing for 3-actin was performed as for loading control.
MMP-9 protein was analysed by zymography (B: *,
unstimulated THP-1 control; 0, CM-stimulated THP-1 cells),
TNF-a protein by bioassay or ELISA (data not shown)
changes in the ability ofCM to induce monocytic proMMP-9 (data
not shown). Further, immunoprecipitation of potential TNF-a
from CM had only a minor effect on its MMP-9-stimulating
activity (Figure 8A). Controls showed that recombinant TNF-oc
could be precipitated efficiently and the TNF-ax antibody 6H 11
was fully removed by protein-G sepharose precipitation. In addi-
tion, preparation of CM in the presence of 30 gM BB-2116, which
blocks TNF-x shedding from the cell surface (Figure 5A),
followed by removal of BB-2116 by gel filtration did not affect
MMP-9 release when this CM was added to the monocytic cells
(Figure 8B). Taken together, these results suggested that tumour
cell-derived TNF-a did not play a major role in stimulation of
monocytic MMP-9 production.
The tumour-derived soluble factor (MMPSF)
Our conclusion from the above experiments was that a tumour
cell-derived soluble factor was synergistic with endogenous
monocytic-produced TNF-ax to stimulate proMMP-9 production.
The factor was heat sensitive; heating to 85°C for 30 min
completely abolished its ability to induce MMP-9 (data not
shown). Preliminary gel filtration experiments indicated a peak of
activity with an apparent molecular mass of 89 kDa. This result
was further evidence that MMPSF was distinct from TNF-ax, as
the molecular mass of TNF-ax has been reported to be 45 kDa by
gel filtration (Aggarwal et al, 1984). A model summarizing our
results is shown in Figure 9.
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Figure 8 The MMP-9 release stimulating activity in CM is not TNF-cx. Immunoprecipitation of TNF-(z potentially present in PEO-1 -derived CM only slightly
altered its capacity to induce MMP-9 release from THP-1 cells (A). Controls showed that recombinant TNF-u. could be precipitated efficiently and the TNF-(z
antibody 6H11 was fully removed by protein-G sepharose precipitation. Control, unstimulated THP-1 cells; AB, TNF- c antibody 6H11; IP, immunoprecipitation;
AimV, culture medium; prot-G Seph, protein-G Sepharose; C-AB, control antibody of same IgG-isotype as 6H11 (IgG1). Statistical analysis using Student's t-test:
CM vs CM+AB, P< 0.001; CM+AB+IP vs CM+AB, P= 0.002). (B) Conditioned medium from PEO-1 cells was prepared in the presence of BB-2116 (30 LM).
Addition of this CM to THP-1 cells in a 1:10 dilution results in a 50% reduction of MMP-9 release from THP-1 cells. When BB-2116 was removed from CM by gel
filtration, the inhibitory effect of BB-2116 disappeared and full MMP-9 stimulation was achieved. Statistical analysis using Student's t-test: control vs CM,
P = 0.009; no spin column, CM vs CM+BB-2116 (3 pM), P = 0.022; after spin column, CM vs CM+BB-2116 (3 pM), P=0.251)
DISCUSSION
In this stUdy. wAe inxestigated the interactions between humanl
oxarilan cancer cells avnd monocytic cells with respect to MMP-9
production and the role of- TNF- in this process. Our results
showed that co-cultures of the ox arian canicer- cell line PEO- I and
the nmonocotic cell line THP- I led to ain increase of proMMP-9 in
the CcIl cuLltuLl-e supciirnatanit. Ful-ther- experimllenits indicated that the
iioiocvtic cells were the source of proMMP-9 andi that a soluble
factor. MMPSF. presenlt inl tLimoLtr-derixved conditioned mllediuLm
(CM) as suffit'ieCilt to inlduce proMMP-9 produCtioll in both the
monocytic cell line THP- 1 and peripheral blood monocytes.
Exper-imiielnts with neutr-alizingy 'antibodies to TNF- a, the inhibitor
BB-2116. which blocks sheddini of TNF-ot from its memiibrane
spanning precursor, anid Northern anbalysis rexvealed that autocrine
TNF-(xparoduction by the monocytic cells was necessar-y for the
synthesis ol' molnocytic proMMP-9. These experimiients also
showed that. in conitr-ast to MMP-9 prodItctiotn TIMP- I expression
remaillnd unchanged. Finally. MMPSF was fouLnd to be distinct
fromii TNF-oa and that the synergistic actioni of' both MMPSF and
TNF- xvas telCili-ed for mollocytic proMMP-9 production.
This Study was based on obserx ations made on biopsies of
humanll oVarian canicer. In sitLt hybridization and inlmLinlohisto-
chemical studies have revealed similarities in the expi-ession
patterni of MMP-9 mRNA and the disti-ibutioni of titmou---associ-
ated imnacrophages (TAMs) (Naylor et al] 1994). Further- TNF-oc
expressioni hals been localized by in situ hybridization to tumour
areas (Naylor et al. 1994). whereas immitnLohlistochenical
ex'idence has suggested localization of TNF-ou protein and TAMs
(Naylor et al. 1993). To inxestigate the relationship between
moniocytes. tuLmlour cells. TNF-(x and MMP-9. we established a co-
cLIltlt-e systemii consisting of the human oxvarian canicer- cell line
PEO- 1 and the human monocytic cell line THP- or isolated
peripheral blood moniocytes. We obserxed that MMP-9 was
released by the moniocytic cells and found that a soluble, tumour
cell-derixed tfactor. MMPSF. was responsible for this MMP-9
production. These findingts are consistent with the in xixo observa-
tions (Naylor et al. 1993. 1994). Detectiort of TNF-(x mRNA and
proteini in the in x itro system showed that the moniocytic cell line
THP- produced TNF-a. In xixo observations. howexer. haxe
localized TNF- gene expression to the tumoul area (Naylor et al.
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Figure 9 Model of stimulation of monocytic MMP-9 release. A soluble protein derived from ovarian cancer cells acts synergistically with autocrine/paracrine
TNF-(x, leading to monocytic proMMP-9 production
1994) but TNF-ux protein to TAMs. Therefore, in vivo, cells other
than the monocytes might be the source of TNF-cx protein. This
interpretation would also explain the need to concentrate CM to
achieve proMMP-9 production by peripheral blood monocytes. In
summary, we suggest that, in ovarian cancer, TNF-oc gene expres-
sion in epithelial tumour areas leads to low levels oftissue TNF-o,
which promotes, together with tumour-derived MMPSF, mono-
cytic proMMP-9 production. Further experiments have confirmed
this hypothesis. THP-1 cells were preincubated for 16 h. At this
timepoint, THP- I cells ceased to produce TNF-oc, and there was
no detectable TNF-cx in the culture medium. Under these circum-
stances, CM did not induce proMMP-9. In addition, CM-induced
MMP-9 production does not affect TIMP- I gene expression,
suggesting a net production ofproteolytic activity. Further work is
required on the observation that, exclusively, the pro-form of
MMP-9 (92 kDa) was detected in the cell culture supernatants.
Production of monocytic proMMP-9 has been the focus of
several recent papers. T-cell-derived gp-39 (Kiener et al, 1995),
TNF-cx and IL-13 (Saren et al, 1996) were shown to be potent
inducers of monocytic proMMP-9 production. The identity of
MMPSF present in CM from tumour cells remains to date
unknown. TNF-oc was a potential candidate but the experiments
performed showed that MMPSF is distinct from TNF-ox. So far, we
have found that MMPSF is heat sensitive, and the observation that
BB-2116 did not inhibit its release eliminates a series of proteins
for which such an effect has been reported (e.g. TGF-oc, M-CSF,
FasL, etc. (Crowe et al, 1995; Kayagaki et al, 1995; Mullberg et al,
1995; Bennett et al, 1996; Couet et al, 1996; Drummond and
Gearing, 1996; Feehan et al, 1996). Another parameter was
obtained by gel filtration ofCM revealing a peak ofactivity with a
molecular mass of 89 kDa. This excludes IL-13, another potent
stimulus of monocytic proMMP-9 production, as IL- 1f shows a
molecular mass of 17.5 kDa by gel filtration (Schmidt, 1984; Gery
and Schmidt, 1985). The nature of MMPSF and its mechanism of
action are the main focus of our current work.
Our results further suggest a new mechanism of action of
synthetic MMPIs in cancer. MMPIs were originally designed to
reduce excessive MMP activity due to an imbalance ofMMPs and
their natural inhibitors (TIMPs). However, synthetic MMPIs also
inhibit shedding of TNF-ox from its membrane spanning precursor
(Gearing et al, 1994, 1995) and of other cytokines: TGF-oc, FasL,
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IL-6 receptor, stem cell factor, M-CSF, TNF-oc receptors, L-
selectin and thyrotropin receptor ectodomain (Crowe et al, 1995;
Kayagaki et al, 1995; Mullberg et al, 1995; Bennett et al, 1996;
Couet et al, 1996; Drummond and Gearing, 1996; Feehan et al,
1996). Therefore, inhibition ofrelease ofcytokines that play a role
in tumour development represents an alternative or additional
mechanism ofaction of MMPIs. This option might be ofparticular
importance if the cytokine has stimulatory activity on MMP gene
expression, as is the case for TNF-ot. However, the IC50 values of
synthetic MMPIs for MMPs are generally 10- to 100-fold lower
than those that influence cytokine release (Chirivi et al, 1994;
Gearing et al, 1994). Hence, the effect might only be a secondary
one to MMP inhibition. However, because of the broad activities
of cytokines and their potency, even small changes might
contribute to the observations made in animal models of human
cancer (Talbot and Brown, 1996) or in current clinical trials.
In this study, we established a simple in vitro system that
allowed us to analyse the mechanisms leading to monocytic
MMP-9 production. Our in vitro findings were in keeping with the
observations made on biopsy material of human ovarian cancer.
Further studies are required to fully characterize MMPSF and to
determine the biological role of the 92-kDa pro-form of MMP-9.
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